Disease · EFO_0002546
abnormal glucose tolerance
6 sourcesdiseases-2026-09-18-0.1.0
Cite this record
ConductScience Library. abnormal glucose tolerance. Diseases, record EFO_0002546. Release diseases-2026-09-18-0.1.0, 18 Sept 2026. https://conductscience.org/library/diseases/EFO_0002546
On this page
Disease
Names and IDs as Open Targets gives them. Its IDs in MeSH, Orphanet, the Disease Ontology and the NCI Thesaurus are those Open Targets states for it.
- Name
- abnormal glucose tolerance
- Open Targets ID
- EFO_0002546
- Other names
- Glucose intolerance
- Highest stage of its drugs
- Phase 3, for 6 of its 35 drugs, from ClinicalTrials.gov
Source Open Targets
Drugs35
The drugs Open Targets' clinical reports study for the disease, the highest stage first, then the most trial reports. The stage is Open Targets', the highest any of its sources reports for the pair, and each row names the sources that report it.
| Drug | ChEMBL ID | Type | Open Targets' stage | Stage reported by | Reports | Of them trials | Trials shown here | Source |
|---|---|---|---|---|---|---|---|---|
| ROSIGLITAZONE | CHEMBL121 | Small molecule | Phase 3 | ClinicalTrials.gov | 3 | 3 | 3 | Drugs and targets |
| EPLERENONE | CHEMBL1095097 | Small molecule | Phase 3 | ClinicalTrials.gov | 1 | 1 | 1 | Drugs and targets |
| MELATONIN | CHEMBL45 | Small molecule | Phase 3 | ClinicalTrials.gov | 1 | 1 | 1 | Drugs and targets |
| RAMIPRIL | CHEMBL1168 | Small molecule | Phase 3 | ClinicalTrials.gov | 1 | 1 | 1 | Drugs and targets |
| SPIRONOLACTONE | CHEMBL1393 | Small molecule | Phase 3 | ClinicalTrials.gov | 1 | 1 | 1 | Drugs and targets |
| TADALAFIL | CHEMBL779 | Small molecule | Phase 3 | ClinicalTrials.gov | 1 | 1 | 1 | Drugs and targets |
| METFORMIN | CHEMBL1431 | Small molecule | Phase 2/3 | ClinicalTrials.gov | 4 | 4 | 4 | Drugs and targets |
| ATORVASTATIN | CHEMBL1487 | Small molecule | Phase 2/3 | ClinicalTrials.gov | 1 | 1 | 1 | Drugs and targets |
| TAURURSODIOL | CHEMBL272427 | Small molecule | Phase 2/3 | ClinicalTrials.gov | 1 | 1 | 0 | Drugs and targets |
| URSODIOL | CHEMBL1551 | Small molecule | Phase 2/3 | ClinicalTrials.gov | 1 | 1 | 1 | Drugs and targets |
1 to 10 of 35
See all 35 drugsTargets79
The targets ChEMBL's mechanism records give for the disease's drugs, through Open Targets, the most drugs first. A mechanism record says what a drug acts on, not that the target causes the disease.
| Target | Protein | Its drugs that act on it | Mechanisms | Highest stage of those drugs | Gene in Genes | Source |
|---|---|---|---|---|---|---|
| CFTR | Cystic fibrosis transmembrane conductance regulator | 4 | Cystic fibrosis transmembrane conductance regulator activator; Cystic fibrosis transmembrane conductance regulator positive modulator; Cystic fibrosis transmembrane conductance regulator stabiliser | Unknown | https://conductscience.org/library/genes/1080 | Drugs and targets |
| DPP4 | Dipeptidyl peptidase 4 | 3 | Dipeptidyl peptidase IV inhibitor | Phase 2 | https://conductscience.org/library/genes/1803 | Drugs and targets |
| AGTR1 | Type-1 angiotensin II receptor | 2 | Type-1 angiotensin II receptor antagonist | Phase 2 | https://conductscience.org/library/genes/185 | Drugs and targets |
| NR3C1 | Glucocorticoid receptor | 2 | Glucocorticoid receptor agonist; Glucocorticoid receptor antagonist | Phase 1/2 | https://conductscience.org/library/genes/2908 | Drugs and targets |
| NR3C2 | Mineralocorticoid receptor | 2 | Mineralocorticoid receptor antagonist | Phase 3 | https://conductscience.org/library/genes/4306 | Drugs and targets |
| PPARG | Peroxisome proliferator-activated receptor gamma | 2 | Peroxisome proliferator-activated receptor gamma agonist | Phase 3 | https://conductscience.org/library/genes/5468 | Drugs and targets |
| ACE | Angiotensin-converting enzyme | 1 | Angiotensin-converting enzyme inhibitor | Phase 3 | https://conductscience.org/library/genes/1636 | Drugs and targets |
| ADORA1 | Adenosine receptor | 1 | Adenosine receptor antagonist | Phase 2 | https://conductscience.org/library/genes/134 | Drugs and targets |
| ADORA2A | Adenosine receptor | 1 | Adenosine receptor antagonist | Phase 2 | https://conductscience.org/library/genes/135 | Drugs and targets |
| ADORA2B | Adenosine receptor | 1 | Adenosine receptor antagonist | Phase 2 | https://conductscience.org/library/genes/136 | Drugs and targets |
1 to 10 of 79
See all 79 targetsTrials29
Trials an Open Targets clinical report links to the disease, posted results first, then the largest. A trial is shown when the release's checks confirm its link to the disease and Drugs and targets shows its link to one of the disease's drugs.
| Trial | Title | Phase | Participants | Results first posted | Conditions | Drugs | Linked by | Source |
|---|---|---|---|---|---|---|---|---|
| NCT01444651 | A Trial of Tadalafil and Glycemic Traits | Phase 3 | 73 | 2017-01-30 | Cardiovascular Disease, Insulin Resistance, Glucose Intolerance, Obesity | TADALAFIL | Its record names the disease | ClinicalTrials.gov |
| NCT02621060 | Effect of Chlorogenic Acid on Patients With Impaired Glucose Tolerance | Phase 2 | 30 | 2019-08-02 | Impaired Glucose Tolerance | CHLOROGENIC ACID | Open Targets' reading of its record | ClinicalTrials.gov |
| NCT01950039 | Metabolic Effects of Betaine Supplementation | Phase 2 | 28 | 2021-04-20 | Obesity, Dysglycemia | BETAINE | Its record names the disease | ClinicalTrials.gov |
| NCT01879228 | Effect of Chronic Incretin-based Therapy in Cystic Fibrosis | Not applicable | 26 | 2022-02-09 | Cystic Fibrosis, Pancreatic Insufficiency | SITAGLIPTIN | Its record names the disease | ClinicalTrials.gov |
| NCT01003275 | Metabolic Effects of Paricalcitol | Phase 2 | 22 | 2013-09-27 | Chronic Kidney Disease | PARICALCITOL | Its record names the disease | ClinicalTrials.gov |
| NCT01419535 | Mifepristone Effects on Glucose Intolerance in Obese/Overweight Adults | Phase 1/2 | 19 | 2021-04-14 | Endocrine Disease, Diabetes | MIFEPRISTONE | Its record names the disease | ClinicalTrials.gov |
| NCT05500937 | Effect of UDCA on the New Onset Diabetes and Glucose Intolerance Induced by Statin | Phase 2/3 | 1,000 | Diabetes Mellitus | ATORVASTATIN, URSODIOL | Its record names the disease | ClinicalTrials.gov | |
| NCT06331000 | Effect of One Year Elexacaftor-tezacaftor-ivacaftor Treatment | 184 | Cystic Fibrosis | ELEXACAFTOR, IVACAFTOR, TEZACAFTOR | Open Targets' reading of its record | ClinicalTrials.gov | ||
| NCT05515978 | Pragmatic Trial of Metformin for Glucose Intolerance or Increased BMI in Prostate Cancer Patients | Early phase 1 | 100 | Prostate Cancer | METFORMIN | Its record names the disease | ClinicalTrials.gov | |
| NCT00489229 | To Investigate the Effect of Rosiglitazone and Ramipril on Pre-clinical Vasculopathy in Diabetes and IGT Patients | Phase 3 | 66 | Diabetes, Impaired Glucose Tolerance | RAMIPRIL, ROSIGLITAZONE | Open Targets' reading of its record | ClinicalTrials.gov |
1 to 10 of 29
See all 29 trialsComparisons in its trials9
Comparisons Trial comparisons calculated in the trials shown here, most participants first. A comparison in one of these trials does not always compare a treatment for the disease, so read the two groups.
| Comparison | Group 1, with the outcome | Group 2, with the outcome | Participants | Trial | Source |
|---|---|---|---|---|---|
| Tadalafil vs Placebo: serious adverse events | 0 of 36 | 0 of 37 | 73 | NCT01444651 | Trial comparisons |
| During/After Paricalcitol vs During/After Placebo: serious adverse events | 0 of 22 | 0 of 21 | 43 | NCT01003275 | Trial comparisons |
| Post-mifepristone vs Post-placebo: deaths from any cause | 0 of 16 | 0 of 16 | 32 | NCT01419535 | Trial comparisons |
| Post-mifepristone vs Post-placebo: serious adverse events | 0 of 16 | 0 of 16 | 32 | NCT01419535 | Trial comparisons |
| Chlorogenic Acid vs Placebo: serious adverse events | 0 of 15 | 0 of 15 | 30 | NCT02621060 | Trial comparisons |
| Betaine vs Placebo: deaths from any cause | 0 of 14 | 0 of 13 | 27 | NCT01950039 | Trial comparisons |
| Betaine vs Placebo: serious adverse events | 0 of 14 | 0 of 13 | 27 | NCT01950039 | Trial comparisons |
| Sitagliptin vs Placebo: deaths from any cause | 0 of 13 | 0 of 13 | 26 | NCT01879228 | Trial comparisons |
| Sitagliptin vs Placebo: serious adverse events | 0 of 13 | 0 of 13 | 26 | NCT01879228 | Trial comparisons |
Papers from its trials18
The papers the trials shown here list on ClinicalTrials.gov as their results (RESULT) or as drawn from them (DERIVED), results first, newest first.
Data dates
The date of each source this release read.
Sources 6
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- NLM's MeSHNLM's terms
- Open TargetsCC0 1.0
- PubMedNLM's terms
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- NLM's MeSHNLM's
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this disease from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/diseases/v1/EFO_0002546
GET https://conductscience.org/api/diseases/v1/EFO_0002546/drugs?page=2